MEtatastic Renal Carcinoma LINes

Centre Hospitalier Universitaire de Besancon440 enrolled

Overview

The hypothesis of this study are as follows: * Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals. * In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities. * The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.

Study Type

OBSERVATIONAL

Enrollment

440

Conditions

Renal Cell Carcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. Patients with locally advanced or metastatic renal cell carcinoma 2. Whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor; 3. Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance Status) at treatment initiation time 4. With first-line treatment carried out between 2007 and June 2016. Exclusion criteria: 1. Patient previously treated with only one cytokine (Interferon α2a, high-dose interleukin-2) 2. Refusal of processing of personal data

Locations (8)

CHU de Besançon

Besançon, France

Hôpital Henri Mondor

Créteil, France

Hôpital Nord Franche-Comté Montbéliard

Montbéliard, France

Hôpital Cochin

Paris, France

Outcomes

Primary Outcomes

Overall survival after the first line of treatment

Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause.

Time frame: year 11

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.